Pericarditis
Drug research and approvals for pericarditis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 14 studies of pericarditis are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 1 approved and 7 open orphan designations naming it.
- Recruiting worldwide: 14
- Trials authorized in Canada: 5
- FDA orphan approvals: 1
- EU medicines: 0
- Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac PatientsNCT07913152 · Not applicable · Tel-Aviv Sourasky Medical Center · starts Jun 17, 2026
- CACP: Study on Camptodactyly - Arthropathy - Coxa Vara - Pericarditis (CACP) SyndromeNCT07468461 · Not reported · Meyer Children's Hospital IRCCS · starts Aug 1, 2025
- Multimodal Analysis of Endomyocardial BiopsiesNCT07359690 · Not reported · University Hospital, Essen · starts Oct 27, 2025
- Transition to KPL-387 Monotherapy Dosing & Administration StudyNCT07288216 · Phase 2 · Kiniksa Pharmaceuticals International, plc · starts Mar 25, 2026
- Pericardial Imaging StudyNCT07245849 · Phase 3 · Ottawa Heart Institute Research Corporation · starts Jun 17, 2026
- EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular DiseasesNCT07077304 · Not reported · Assistance Publique - Hôpitaux de Paris · starts Nov 19, 2025
- Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387NCT07010159 · Phase 2 / Phase 3 · Kiniksa Pharmaceuticals International, plc · starts Jul 25, 2025
- An Open-Label Pilot Study of VTX2735 in Recurrent PericarditisNCT06836232 · Phase 2 · Zomagen Biosciences Ltd. · starts Jan 28, 2025
- CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)NCT06708299 · Phase 3 · Cardiol Therapeutics Inc. · starts Apr 7, 2025
Approved 1
- RilonaceptInterleukin-1 beta inhibitor
Phase 3 5
- ColchicineTubulin inhibitor
- Goflikicept
- AnakinraInterleukin-1 receptor antagonist
- PrednisoneGlucocorticoid receptor agonist
- HydroxychloroquineFerriprotoporphyrin IX inhibitor
Phase 2 1
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
How its trials ended
46 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 14 whose ending is known, 50% met their primary endpoint, 7% missed it and 43% stopped early.
- Ongoing1839%
- Completed, result not reported817%
- Met its primary endpoint715%
- Status unknown613%
- Stopped: other or unclear511%
- Missed its primary endpoint12%
- Stopped: enrollment or feasibility12%
| Nov 14, 2025 | A phase 2a, open-label pilot study to evaluate the safety/tolerability, efficacy, pharmacokinetics, and pharmacodynamics of VTX2735 in participants with…LY5625574 (VTX2735) | Zomagen Biosciences Ltd. | Ongoing |
| Nov 7, 2025 | A phase 2 posology study with long-term extension in participants with well controlled recurrent pericarditis to evaluate the efficacy and safety of transition…KPL-387 (antithrombin concentrate) | Kiniksa Pharmaceuticals (UK) | Ongoing |
| Jul 23, 2025 | A phase 2/3 efficacy and safety study of KPL-387 treatment in participants with recurent pericarditisKPL-387 | Kiniksa Pharmaceuticals (UK) | Pending |
| Feb 27, 2025 | Identifying clinical, serum, and imaging based biomarkers associated with high-risk phenotypes for recurrent pericarditis: a prospective cohort study18F-fluorodeoxyglucose (18F-FDG) | Ottawa Heart Institute Research Corporation | Ongoing |
| Nov 19, 2024 | Impact of cardiolrx over 6 months following IL-1 blocker cessation in pericarditis patients - maveric-2. a randomized, double-blind, placebo-controlled trialCannabidiol (cardiolrx) | Cardiol Therapeutics Inc | Ongoing |
| Mar 18, 2021 | ArcalystTreatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older | Kiniksa Pharmaceuticals, Ltd. | Approved |
| Feb 13, 2026 | Peripherally restricted, selective, small molecule…Treatment of pericarditis | Zomagen Biosciences Ltd, a wholly owned subsidiary of Ventyx Biosciences, Ltd. | Designated |
| Dec 31, 2025 | ColchicineTreatment of pericarditis | Pharmascience Inc. | Designated |
| Oct 16, 2025 | Fully human IgG2 monoclonal antibody that blocks…Treatment of pericarditis | Kiniksa Pharmaceuticals,GmbH,c/o Kiniksa Pharmaceuticals Corp | Designated |
| Apr 16, 2025 | ColchicineTreatment of pericarditis | Scilex Pharmaceuticals Inc. | Designated |
| Oct 11, 2024 | GoflikiceptTreatment of pericarditis | R-Pharm Overseas, Inc. | Designated |
| Oct 9, 2024 | ColchicineTreatment of pericarditis | ACARPIA Farmaceutici S.r.l. | Designated |
| Feb 14, 2024 | CannabidiolTreatment of pericarditis. | Cardiol Therapeutics Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA